Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunology & Th2-Mediated Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for STAT6 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | STAT6 Full-Length / SH2 Domain / DNA-Binding Domain Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View STAT6 Products |
| Gene Delivery | STAT6 Promise-ORF / Lentivirus Premade Particles Full-length ORF for stable cell line construction. Titer >1×10⁸ TU/mL. |
View STAT6 Products |
| Benchmark Ab | Anti-STAT6 Antibody Recombinant positive control for western/ELISA. |
View STAT6 Products |
| Validator | STAT6 siRNA Set (3 unique sequences) For knockdown verification and specificity controls. Endotoxin controlled. |
View STAT6 Products |
| Related Target - STAT3 | STAT3 SH2 Domain Protein Off-target selectivity screening (high homology family member). |
View STAT3 Products |
| Related Target - IL-4Rα | IL-4Rα ECD-Fc Fusion Protein Upstream pathway component for ligand competition assays. |
View IL-4Rα Products |
| Related Target - IL-13Rα1 | IL-13Rα1 Recombinant Protein Critical heterodimeric partner for IL-13 signaling. |
View IL-13Rα1 Products |
| Related Target - JAK1 | JAK1 Protein Kinase responsible for STAT6 phosphorylation. |
View JAK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PROTAC / Degrader Binding Validation | High-purity (>95%) recombinant STAT6 protein optimized for SPR/BLI binding assays. |
| STAT Family Selectivity (SH2 domain homology) | Homolog Panel: STAT1, STAT3, STAT5A, STAT5B SH2 domains. Sequence Verified, >95% purity. Mass spec confirmed identity. |
| Phosphorylation State Detection (pSTAT6 Y641) | Phospho-STAT6 (Y641) Mutant Proteins available. Theoretical MW confirmed for Western blot standards. |
| Intracellular Delivery Validation | Cell-permeable controls: STAT6 Lentivirus for stable overexpression cell lines. HEK293 Expressed, native folding. |
| DNA Binding Activity Screening | DNA-Binding Domain (DBD) truncations available. Sequence Verified for EMSA/ChIP assays. |
| Knockdown Specificity Controls | Validated siRNA Set included. Endotoxin controlled for cell-based assays. |
Live STAT6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for STAT6 therapeutics is intensifying, with major players shifting focus from upstream biologic blockade (like anti-IL4R) to direct intracellular targeting via small molecules and PROTACs. As first-generation therapies for asthma and atopic dermatitis establish the clinical validity of the Th2 pathway, the next wave of R&D is targeting direct STAT6 inhibition to provide oral alternatives to injectable monoclonal antibodies. The STAT6 inhibitor landscape is rapidly evolving from traditional broad immunosuppressants toward precision-targeted Th2 pathway modulation. With the failure of broad JAK inhibitors in certain indications due to safety profiles, pharmaceutical players are increasingly targeting downstream transcription factors like STAT6 for allergic diseases and specific lymphoma subtypes. The next wave of R&D focuses on PROTAC-mediated degradation and allosteric SH2 domain inhibitors that offer superior selectivity over pan-STAT compounds.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (SH2 inhibitor) | Kymera, Nurix, Internal pipelines | Severe Asthma, Atopic Dermatitis | Selectivity Panel (STAT1/3/5 vs STAT6). Need purified SH2 domains. |
| PROTAC / Degrader | Arvinas, C4 Therapeutics, Early-stage Biotechs | Asthma, Atopic Dermatitis, PTCL, CTCL | Full-length STAT6 Protein for ternary complex formation assays; Degradation Assay (Need high-purity Intracellular Protein) |
| Antisense Oligonucleotides | Ionis, Phase 2 partnerships | Eosinophilic Esophagitis | Knockdown validation using STAT6 siRNA controls. |
| Upstream Biologics / Bispecific | Sanofi, Regeneron (Dupilumab context) | Severe Asthma, Chronic Rhinosinusitis | Pathway completeness: IL-4Rα and IL-13Rα1 antigens; Pathway Validation (Need STAT6 siRNA & Reporter Lines) |
Key STAT6 Functional Domains and Mutations for Assay Development
STAT6 contains an SH2 domain (Src Homology 2) critical for phosphotyrosine recognition and dimerization. Key mutations include:
- rs3024952 (dbSNP): A common variant with unknown clinical significance.
- UniProt VAR_089075: Does not affect DNA-binding transcription factor activity; does not affect STAT6 function.
- UniProt VAR_089076: Associated with hyper-IgE syndrome type 6 (HIES6); likely pathogenic; increased DNA-binding transcription factor activity.
These mutations are essential for designing counter-screening assays to ensure drug candidates do not inadvertently activate or inhibit mutant forms. TarMart offers recombinant STAT6 proteins with specific mutations for selectivity profiling.